Analysis of Uremic Toxins with Mass Spectrometry

Niwa, Toshimitsu

doi:10.1002/9781118424032.ch3

Cited by 4 publications

(1 citation statement)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If these retained solutes have a harmful effect on the body, they are called "uremic toxins". As uremic toxins can cause various symptoms and increase mortality [2], clarifying the profile of uremic solutes is urgently needed for better outcomes in CKD patients. With the progress of identification technology such as mass spectrometry (MS) and nuclear magnetic resonance (NMR), more Toxins 2021, 13, 324 2 of 13 than 100 organic solutes have been identified and reported as uremic solutes or uremic toxins [3][4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

CE-MS-Based Identification of Uremic Solutes Specific to Hemodialysis Patients

Akiyama

Kikuchi

Toyohara

et al. 2021

Toxins

View full text Add to dashboard Cite

Uremic toxins are suggested to be involved in the pathophysiology of hemodialysis (HD) patients. However, the profile of uremic solutes in HD patients has not been fully elucidated. In this study using capillary electrophoresis mass spectrometry (CE-MS), we comprehensively quantified the serum concentrations of 122 ionic solutes before and after HD in 11 patients. In addition, we compared the results with those in non-HD patients with chronic kidney disease (CKD) to identify HD patient-specific solutes. We identified 38 solutes whose concentrations were higher in pre-HD than in CKD stage G5. Ten solutes among them did not significantly accumulate in non-HD CKD patients, suggesting that these solutes accumulate specifically in HD patients. We also identified 23 solutes whose concentrations were lower in both pre- and post-HD than in CKD stage G5. The serum levels of 14 solutes among them were not affected by renal function in non-HD patients, suggesting that these solutes tend to be lost specifically in HD patients. Our data demonstrate that HD patients have a markedly different profile of serum uremic solute levels compared to that in non-HD CKD patients. The solutes identified in our study may contribute to the pathophysiology of HD patients.

show abstract

Section: Introductionmentioning

confidence: 99%

CE-MS-Based Identification of Uremic Solutes Specific to Hemodialysis Patients

Akiyama

Kikuchi

Toyohara

et al. 2021

Toxins

View full text Add to dashboard Cite

show abstract

Overview of Uremic Toxins

Niwa

2020

Uremic Toxins and Organ Failure

View full text Add to dashboard Cite

Metabolome panels as potential noninvasive biomarkers for primary glomerulonephritis sub-types: meta-analysis of profiling metabolomics studies

Roointan,

Ghaeidamini,

Shafieizadegan

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Primary glomerulonephritis diseases (PGDs) are known as the top causes of chronic kidney disease worldwide. Renal biopsy, an invasive method, is the main approach to diagnose PGDs. Studying the metabolome profiles of kidney diseases is an inclusive approach to identify the disease’s underlying pathways and discover novel non-invasive biomarkers. So far, different experiments have explored the metabolome profiles in different PGDs, but the inconsistencies might hinder their clinical translations. The main goal of this meta-analysis study was to achieve consensus panels of dysregulated metabolites in PGD sub-types. The PGDs-related metabolome profiles from urine samples in humans were selected in a comprehensive search. Amanida package in R software was utilized for performing the meta-analysis. Through sub-type analyses, the consensus list of metabolites in each category was obtained. To identify the most affected pathways, functional enrichment analysis was performed. Also, a gene-metabolite network was constructed to identify the key metabolites and their connected proteins. After a vigorous search, among the 11 selected studies (15 metabolite profiles), 270 dysregulated metabolites were recognized in urine of 1154 PGDs and control samples. Through sub-type analyses by Amanida package, the consensus list of metabolites in each category was obtained. Top dysregulated metabolites (vote score of ≥ 4 or ≤ − 4) in PGDs urines were selected as main panel of meta-metabolites including glucose, leucine, choline, betaine, dimethylamine, fumaric acid, citric acid, 3-hydroxyisovaleric acid, pyruvic acid, isobutyric acid, and hippuric acid. The enrichment analyses results revealed the involvement of different biological pathways such as the TCA cycle and amino acid metabolisms in the pathogenesis of PGDs. The constructed metabolite-gene interaction network revealed the high centralities of several metabolites, including pyruvic acid, leucine, and choline. The identified metabolite panels could shed a light on the underlying pathological pathways and be considered as non-invasive biomarkers for the diagnosis of PGD sub-types.

show abstract

Analysis of Uremic Toxins with Mass Spectrometry

Cited by 4 publications

References 56 publications

CE-MS-Based Identification of Uremic Solutes Specific to Hemodialysis Patients

CE-MS-Based Identification of Uremic Solutes Specific to Hemodialysis Patients

Overview of Uremic Toxins

Metabolome panels as potential noninvasive biomarkers for primary glomerulonephritis sub-types: meta-analysis of profiling metabolomics studies

Contact Info

Product

Resources

About